{"id":"https://openalex.org/W2008956595","doi":"https://doi.org/10.1111/j.2042-7158.1997.tb06773.x","title":"Degradation of Insulin and Calcitonin and Their Protection by Various Protease Inhibitors in Rat Caecal Contents: Implications in Peptide Delivery to the Colon","display_name":"Degradation of Insulin and Calcitonin and Their Protection by Various Protease Inhibitors in Rat Caecal Contents: Implications in Peptide Delivery to the Colon","alternate_titles":[],"publication_year":1997,"publication_date":"1997-02-01","ids":{"openalex":"https://openalex.org/W2008956595","doi":"https://doi.org/10.1111/j.2042-7158.1997.tb06773.x","mag":"2008956595","pmid":"https://pubmed.ncbi.nlm.nih.gov/9055189"},"language":"en","primary_location":{"id":"doi:10.1111/j.2042-7158.1997.tb06773.x","doi":"https://doi.org/10.1111/j.2042-7158.1997.tb06773.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.2042-7158.1997.tb06773.x","pdf_url":null,"source":{"id":"https://openalex.org/S118304455","display_name":"Journal of Pharmacy and Pharmacology","issn_l":"0022-3573","issn":["0022-3573","2042-7158"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmacy and Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2008956595"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041813630","display_name":"Hideyuki Tozaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I25998863","display_name":"Kyoto Pharmaceutical University","ror":"https://ror.org/01ytgve10","country_code":"JP","type":"education","lineage":["https://openalex.org/I25998863"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hideyuki Tozaki","raw_affiliation_strings":["Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan","institution_ids":["https://openalex.org/I25998863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044486990","display_name":"Yasuharu Emi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I25998863","display_name":"Kyoto Pharmaceutical University","ror":"https://ror.org/01ytgve10","country_code":"JP","type":"education","lineage":["https://openalex.org/I25998863"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yasuharu Emi","raw_affiliation_strings":["Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan","institution_ids":["https://openalex.org/I25998863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001015503","display_name":"Eri Horisaka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I25998863","display_name":"Kyoto Pharmaceutical University","ror":"https://ror.org/01ytgve10","country_code":"JP","type":"education","lineage":["https://openalex.org/I25998863"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eri Horisaka","raw_affiliation_strings":["Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan","institution_ids":["https://openalex.org/I25998863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103394027","display_name":"Takuya Fujita","orcid":"https://orcid.org/0000-0002-7724-6522","observed_orcids":["https://orcid.org/0000-0002-7724-6522"]},"institutions":[{"id":"https://openalex.org/I25998863","display_name":"Kyoto Pharmaceutical University","ror":"https://ror.org/01ytgve10","country_code":"JP","type":"education","lineage":["https://openalex.org/I25998863"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Takuya Fujita","raw_affiliation_strings":["Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan","institution_ids":["https://openalex.org/I25998863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060619493","display_name":"Akira Yamamoto","orcid":"https://orcid.org/0000-0002-6250-5472","observed_orcids":["https://orcid.org/0000-0002-6250-5472"]},"institutions":[{"id":"https://openalex.org/I25998863","display_name":"Kyoto Pharmaceutical University","ror":"https://ror.org/01ytgve10","country_code":"JP","type":"education","lineage":["https://openalex.org/I25998863"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Akira Yamamoto","raw_affiliation_strings":["Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan","institution_ids":["https://openalex.org/I25998863"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053426908","display_name":"Shozo Muranishi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I25998863","display_name":"Kyoto Pharmaceutical University","ror":"https://ror.org/01ytgve10","country_code":"JP","type":"education","lineage":["https://openalex.org/I25998863"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shozo Muranishi","raw_affiliation_strings":["Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607, Japan","institution_ids":["https://openalex.org/I25998863"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5060619493"],"corresponding_institution_ids":["https://openalex.org/I25998863"],"apc_list":{"value":2911,"currency":"GBP","value_usd":3839},"apc_paid":null,"fwci":3.9117,"has_fulltext":true,"cited_by_count":103,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.94661191,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"49","issue":"2","first_page":"164","last_page":"168"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.9282000064849854,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.9282000064849854,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.018799999728798866,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/insulin-degradation","display_name":"insulin degradation","score":0.8650000095367432},{"id":"https://openalex.org/keywords/protease-inhibitors","display_name":"protease inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/camostat","display_name":"camostat","score":0.8889999985694885},{"id":"https://openalex.org/keywords/aprotinin","display_name":"aprotinin","score":1.0},{"id":"https://openalex.org/keywords/caecal-contents","display_name":"caecal contents","score":0.9679999947547913},{"id":"https://openalex.org/keywords/large-intestine","display_name":"large intestine","score":0.6299999952316284},{"id":"https://openalex.org/keywords/colon-specific-drug-delivery","display_name":"colon-targeted drug delivery","score":0.8289999961853027},{"id":"https://openalex.org/keywords/peptide-stability","display_name":"peptide stability","score":0.7850000262260437},{"id":"https://openalex.org/keywords/chymotrypsin","display_name":"chymotrypsin","score":0.9409999847412109},{"id":"https://openalex.org/keywords/peptide-absorption","display_name":"peptide absorption","score":0.4749999940395355},{"id":"https://openalex.org/keywords/ph-effect-on-degradation","display_name":"pH effect on degradation","score":0.5299999713897705}],"concepts":[{"id":"https://openalex.org/C2780799893","wikidata":"https://www.wikidata.org/wiki/Q418625","display_name":"Aprotinin","level":2,"score":0.8596796989440918},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.8069934844970703},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.6443169116973877},{"id":"https://openalex.org/C2779627488","wikidata":"https://www.wikidata.org/wiki/Q315860","display_name":"Calcitonin","level":2,"score":0.6233553886413574},{"id":"https://openalex.org/C2777882243","wikidata":"https://www.wikidata.org/wiki/Q11090","display_name":"Small intestine","level":2,"score":0.5168426632881165},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4803163409233093},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.44684192538261414},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.437996506690979},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3619565963745117},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.36140328645706177},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30931153893470764},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.27657854557037354},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.25143563747406006}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002116","descriptor_name":"Calcitonin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D002432","descriptor_name":"Cecum","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002432","descriptor_name":"Cecum","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004952","descriptor_name":"Esters","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006146","descriptor_name":"Guanidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006863","descriptor_name":"Hydrogen-Ion Concentration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D007611","descriptor_name":"Aprotinin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010450","descriptor_name":"Endopeptidases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016670","descriptor_name":"Gabexate","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.2042-7158.1997.tb06773.x","doi":"https://doi.org/10.1111/j.2042-7158.1997.tb06773.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.2042-7158.1997.tb06773.x","pdf_url":null,"source":{"id":"https://openalex.org/S118304455","display_name":"Journal of Pharmacy and Pharmacology","issn_l":"0022-3573","issn":["0022-3573","2042-7158"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmacy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:9055189","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9055189","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of pharmacy and pharmacology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W106029644","https://openalex.org/W1520238517","https://openalex.org/W1964794788","https://openalex.org/W1982049263","https://openalex.org/W2027742586","https://openalex.org/W2034307937","https://openalex.org/W2040367683","https://openalex.org/W2040573384","https://openalex.org/W2041020536","https://openalex.org/W2077612925","https://openalex.org/W2087526401","https://openalex.org/W2112331652","https://openalex.org/W2253251593","https://openalex.org/W2316127252","https://openalex.org/W2318943034","https://openalex.org/W2444500546"],"related_works":["https://openalex.org/W2316127252","https://openalex.org/W2324789940","https://openalex.org/W2112331652","https://openalex.org/W2033190444","https://openalex.org/W2060851978","https://openalex.org/W2040290916","https://openalex.org/W2325455825","https://openalex.org/W606243891","https://openalex.org/W1524677047"],"abstract_inverted_index":{"The":[0,83],"objective":[1],"of":[2,10,36,45,52,55,67,74,81,85,102,118,159],"this":[3],"study":[4],"was":[5,40,76,87,111],"to":[6,133,171],"examine":[7],"the":[8,22,34,53,56,72,100,114,134,157,163,172],"metabolism":[9],"insulin":[11,37,60,86,103],"and":[12,14,33,38,61,97,104],"calcitonin,":[13],"their":[15,168],"protection":[16],"by":[17],"various":[18],"protease":[19],"inhibitors,":[20],"in":[21,42,65,106,146,162],"large":[23,57,135,164],"intestine.":[24,58],"Fresh":[25],"caecal":[26,47,69,108,148],"contents":[27],"were":[28,63],"prepared":[29],"from":[30],"non-fasted":[31],"rats":[32],"degradation":[35,73,84,101],"calcitonin":[39,62,75,105],"studied":[41],"a":[43,50],"suspension":[44],"rat":[46,68,107,147],"contents,":[48,70,109],"as":[49,95],"model":[51],"content":[54],"Both":[59],"metabolized":[64],"suspensions":[66],"but":[71],"much":[77],"faster":[78],"than":[79],"that":[80,124],"insulin.":[82],"fastest":[88],"at":[89],"pH":[90],"6.8.":[91],"Protease":[92,150],"inhibitors":[93,151],"such":[94],"camostat":[96],"aprotinin":[98],"inhibited":[99],"which":[110],"consistent":[112],"with":[113],"high":[115],"chymotrypsin":[116],"activity":[117],"these":[119,160],"contents.":[120,149],"These":[121],"findings":[122],"suggest":[123],"care":[125],"should":[126],"be":[127,144,153],"taken":[128],"when":[129],"administering":[130],"peptide":[131],"drugs":[132],"intestine":[136],"for":[137,155],"colon-specific":[138],"drug":[139],"delivery":[140],"because":[141],"they":[142],"can":[143],"degraded":[145],"might":[152],"useful":[154],"increasing":[156],"stability":[158],"peptides":[161],"intestine,":[165],"thereby":[166],"improving":[167],"large-intestinal":[169],"absorption":[170],"systemic":[173],"circulation.":[174]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2008956595","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-22T12:46:00.618207","created_date":"2016-06-24T00:00:00"}
